OP-04 Initial tumour response after short and long interval chemoembolization with drug-eluting beads (DC-Beads) in hepatocellular carcinoma – A pilot study

Syha, Roland; Ketelsen, Dominik; Heller, SJ; Schmehl, Jörg; Mangold, Stefanie; Heuschmid, Martin; Claussen, Claus D.; Schick, F; Brechtel, Klaus

doi:10.1016/s1590-8658(13)60668-4

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is concordant to a study which reported that shorter retreatment time intervals (eg, 6 weeks in comparison to 12 weeks) could provoke a favorable outcome in cases with tumor residuals after DEB-TACE. 11 Only few studies dealt with PBV measurements acquired by C-arm CT. These studies focus on comparison of VPCT parameters to PBV measurements.…”

Section: Discussionmentioning

confidence: 99%

Parenchymal Blood Volume Assessed by C-Arm–Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma

Syha

Grözinger

Grosse³

et al. 2016

Investigative Radiology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Parenchymal Blood Volume Assessed by C-Arm–Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma

Syha

Grözinger

Grosse³

et al. 2016

Investigative Radiology

View full text Add to dashboard Cite

show abstract

“…In several studies, DEB-TACE offered higher rates of treatment response compared to Conv-TACE. The local recurrence or progression rate, however, could not be ignored (12,13,(19)(20)(21) and the possibility of repetitive TACE should be considered even after a successful initial TACE. Most patients with HCC require repeated TACE sessions.…”

Section: Discussionmentioning

confidence: 99%

Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study

et al. 2016

View full text Add to dashboard Cite

Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. Purpose To investigate the incidence and predictors of hepatic arterial damage (HAD) after drug-eluting bead-TACE (DEB-TACE) in comparison with conventional TACE (Conv-TACE). Material and Methods We retrospectively analyzed 54 patients who underwent DEB-TACE for HCC as an initial treatment with follow-up angiography and 54 patients who underwent Conv-TACE using doxorubicin-lipiodol mixture and gelfoam particles for comparison. HAD was evaluated after a single session of TACE and graded as follows: grade I, no significant wall irregularity; grade II, overt stenosis; grade III, occlusion. Results The incidence of HAD was significantly higher in the DEB-TACE group than the Conv-TACE group when analyzed per branch (odds ratio [OR], 6.36; P < 0.001) and per patient (OR, 3.15; P = 0.005). For each HAD grade, the mean doxorubicin dose was greater in the DEB-TACE group than in the Conv-TACE group ( P < 0.001, P = 0.053, and P = 0.01 for grades I, II, and III, respectively). In multivariate analysis, risk factors of HAD included mean doxorubicin dose and selective embolization in the Conv-TACE group ( P = 0.03 and P < 0.001, respectively) and mean doxorubicin dose in the DEB-TACE group ( P = 0.004). Conclusion The incidence and grade of HAD were higher after DEB-TACE compared to Conv-TACE with doxorubicin dose as a possible risk factor. HAD was independent of overall survival in both groups.

show abstract

“…The arterial input function value is calculated from an automated histogram analysis of the vessel tree and applied as a scaling factor to obtain the actual PBV map [ 12 ]. Technical details of image acquisition and post-processing using an automatic reconstruction algorithm, as described previously, are given in Supplemental Table 1 [ 3 , 8 , 9 ].…”

Section: Methodsmentioning

confidence: 99%

Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: Impact of Embolic Density and Residual Tumor Perfusion on Tumor Recurrence and Survival

Ruff¹,

Artzner²,

Syha

et al. 2021

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose To evaluate the value of dual-phase parenchymal blood volume (PBV) C-arm mounted cone-beam-CT (CBCT) to enable assessment of radiopaque, doxorubicin-loaded drug-eluting embolics (rDEE) based on the visual degree of embolization, embolic density and residual tumor perfusion as early predictors for tumor recurrence after transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). Material and Methods Thirty patients (50 HCCs) were prospectively enrolled, underwent cross-sectional imaging before and after TACE using 100–300 µm rDEE and had regular follow-up examinations. Directly before and after the TACE procedure, PBV-CBCT was acquired. The response was evaluated and compared to visual degree of embolization (DE) and embolic density (ED) of rDEE deposits, as well as the presence of residual tumor perfusion (RTP) derived from PBV-CBCT. Outcome was assessed by mid-term tumor response applying mRECIST and patient survival after 12 months. Results RTP was detected in 16 HCCs and correlated negatively with DE (p = .03*) and ED (p = .0009*). The absence of RTP significantly improved lesion-based mid-term response rates regarding complete response (CR, 30/34 (88%) vs 2/16 (12.5%), p = .0002*), lesion-based complete response rate was 75% (21/28) for DE ≥ 50% vs. 50% (11/22) for DE < 50% (p = .08) and 82% (27/33) for ED ≥ 2 vs. 29% for ED < 2 (5/17), p = .005*). Thirteen patients were treated with re-TACE within 12 months, 11 of which had shown RTP. 12-month survival rate was 93%. Conclusion Residual tumor perfusions as assessed by PBV-CBCT during rDEE-TACE proved to be the best parameter to predict mid-term response. “Level of Evidence: Level 3”

show abstract

OP-04 Initial tumour response after short and long interval chemoembolization with drug-eluting beads (DC-Beads) in hepatocellular carcinoma – A pilot study

Cited by 6 publications

References 0 publications

Parenchymal Blood Volume Assessed by C-Arm–Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma

Parenchymal Blood Volume Assessed by C-Arm–Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma

Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study

Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: Impact of Embolic Density and Residual Tumor Perfusion on Tumor Recurrence and Survival

Contact Info

Product

Resources

About